<code id='01AC237B7A'></code><style id='01AC237B7A'></style>
    • <acronym id='01AC237B7A'></acronym>
      <center id='01AC237B7A'><center id='01AC237B7A'><tfoot id='01AC237B7A'></tfoot></center><abbr id='01AC237B7A'><dir id='01AC237B7A'><tfoot id='01AC237B7A'></tfoot><noframes id='01AC237B7A'>

    • <optgroup id='01AC237B7A'><strike id='01AC237B7A'><sup id='01AC237B7A'></sup></strike><code id='01AC237B7A'></code></optgroup>
        1. <b id='01AC237B7A'><label id='01AC237B7A'><select id='01AC237B7A'><dt id='01AC237B7A'><span id='01AC237B7A'></span></dt></select></label></b><u id='01AC237B7A'></u>
          <i id='01AC237B7A'><strike id='01AC237B7A'><tt id='01AC237B7A'><pre id='01AC237B7A'></pre></tt></strike></i>

          focus

          focus

          author:hotspot    Page View:6
          Judge's gavel
          Legal experts unpacked the pharmaceutical industry's scattershot approach to challenging Medicare's new power to negotiate drug prices. Adobe

          WASHINGTON — The pharmaceutical industry has been filing a lawsuit here, there, and pretty much everywhere.

          Drugmakers lost a two-decade long lobbying fight in Congress last summer when Democrats gave Medicare more power to choose what it pays for prescription drugs. Now, they’re taking their battle to the courts.

          advertisement

          Merck filed suit in the District of Columbia. Bristol Myers Squibb filed in New Jersey. The Chamber of Commerce filed in Ohio. PhRMA filed in Texas. And there’s no reason to believe the barrage of lawsuits will stop anytime soon.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

          CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

          read more
          Feng Zhang suggests Editas didn’t move quickly enough to find product targets
          Feng Zhang suggests Editas didn’t move quickly enough to find product targets

          ScientistFengZhang,right,isinterviewedbyreporterMeganMolteniatSTAT'sBreakthroughSummitEast.STATWhent

          read more
          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more

          'Cuddling' is just what the doctor ordered for a 200

          InthisphotoprovidedbytheAlaskaSeaLifeCenter,WildlifeResponseAnimalCareSpecialistsHalleyWerner,left,a